PISCATAWAY, N.J., June 4, 2026
Kashiv BioSciences has announced a significant regulatory milestone with the validation and acceptance by Health Canada of its Market Authorization Application (MAA) for ADL-018, the company’s proposed biosimilar to XOLAIR® (omalizumab). The acceptance marks an important step forward in Kashiv’s expanding biosimilars portfolio and reinforces the company’s commitment to increasing global access to affordable biologic therapies. Omalizumab is a widely used monoclonal antibody indicated for multiple allergic and immunological conditions, including moderate-to-severe persistent asthma, chronic spontaneous urticaria, chronic rhinosinusitis with nasal polyps, and IgE-mediated food allergies. The latest regulatory progress positions Kashiv closer to introducing a cost-effective biosimilar alternative to Canadian patients while strengthening competition in the growing biologics market. As healthcare systems worldwide seek solutions to improve treatment affordability without compromising quality, biosimilars continue to play an increasingly important role in expanding patient access to advanced therapies.
Health Canada Acceptance Marks Key Regulatory Milestone
The acceptance of the marketing authorization application by Health Canada represents a major achievement for Kashiv BioSciences and validates the extensive analytical, manufacturing, and development work undertaken to support ADL-018. Regulatory acceptance indicates that Health Canada has completed its preliminary review and determined that the submission contains the necessary data required for a full scientific evaluation. The milestone moves ADL-018 into the next stage of regulatory review and brings the company closer to potential commercialization in Canada.
According to Kashiv leadership, the achievement reflects the strength of the company’s integrated development platform, which combines research, clinical development, manufacturing, regulatory expertise, and quality systems under one organization. The advancement of ADL-018 also highlights the increasing maturity of the global biosimilar sector, where highly comparable biologic alternatives are helping reduce healthcare costs while maintaining rigorous standards for safety, efficacy, and quality.
ADL-018 Targets Growing Demand for Biologic Therapies
Advertisement
ADL-018 is being developed as a biosimilar to XOLAIR® (omalizumab), a humanized monoclonal antibody that works by targeting and neutralizing free immunoglobulin E (IgE), a critical mediator of allergic and inflammatory responses. Omalizumab has become an established treatment option for patients suffering from severe allergic diseases that remain inadequately controlled with standard therapies. The biologic is approved for use across several indications, including persistent allergic asthma, chronic spontaneous urticaria, chronic rhinosinusitis with nasal polyps, and IgE-mediated food allergies.
ADL-018 has been designed to match the reference product’s dosage strength, route of administration, pharmaceutical presentation, and dosing regimen. By offering a biosimilar alternative, Kashiv aims to increase treatment accessibility and provide healthcare systems with additional options for managing chronic allergic conditions. Market data indicate that annual Canadian sales of the reference product exceeded $135 million, underscoring the substantial demand for omalizumab-based therapies and the commercial opportunity associated with introducing a high-quality biosimilar.
Expanding Global Biosimilar Presence Through Strategic Partnerships
The development of ADL-018 is supported through Kashiv BioSciences’ strategic collaboration with Alvotech, a partnership focused on advancing the proposed omalizumab biosimilar across Canada, the European Economic Area, the United Kingdom, Switzerland, Australia, and New Zealand. The collaboration combines Kashiv’s vertically integrated biosimilar capabilities with Alvotech’s expertise in biologics development and commercialization. Kashiv is among a select group of U.S.-based biopharmaceutical companies that have successfully manufactured and secured marketing authorization for multiple biosimilars, positioning the company as an emerging force in the global biologics landscape.
As biosimilars continue to reshape healthcare markets by improving affordability and access, regulatory milestones such as the Health Canada acceptance of ADL-018 demonstrate ongoing momentum in the sector. If approved, the proposed biosimilar could provide Canadian patients and healthcare providers with a valuable new treatment option while contributing to broader efforts aimed at expanding access to life-changing biologic medicines.
Source: Kashiv BioSciences press release
